WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL - Jonathan Barratt; Jens Kristensen; Andrew Stone; Jürgen Floege; Vladimír Tesař; Hernán Trimarchi; Hong Zhang; Necmi Eren; Alexander Paliege; Heather N. Reich; Brad H. Rovin; Richard Lafayette (Kidney International Reports)